Navigation Links
Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial

LONDON, 12 July 2007 - Cancer drug developer Antisoma plc (LSE: ASM, US OTC: ATSMY) today announces new data from its phase II trial of ASA404 in recurrent, platinum-sensitive ovarian cancer. This trial compares patients receiving ASA404 plus chemotherapy (n=37) with patients receiving chemotherapy alone (n=38). The main findings are as follows:

* There was no advantage in median time to tumour progression in the ASA404 arm compared with the control arm * One-year survival rates were 74% for the ASA404 arm and 92% for the control arm. Since the majority of patients in both arms were alive after one year, median survival values have not been determined * Independently-determined response rates were consistent with those previously reported from investigator assessment and showed a higher response rate in the ASA404 arm * Addition of ASA404 to chemotherapy was generally well tolerated.

Based on these data, development in ovarian cancer will not be a priority.

Antisoma has been testing ASA404 in several cancer types and previously reported a 5-month increase in median survival when the drug was added to chemotherapy in non-small cell lung cancer.

Antisoma licensed ASA404 to Novartis in April 2007. Novartis plans to start enrolling patients into a phase III trial in non-small cell lung cancer early in 2008 and to explore the potential benefits of the compound in various other solid tumours.

Glyn Edwards, Antisoma's CEO said, "Our ovarian cancer trial has not produced positive results like those seen with ASA404 in lung cancer. More broadly, we're very pleased with the progress made by Novartis to date with ASA404 in lung cancer and look forward to working with them to fully evaluate the drug in other cancers."

Enquiries: Glyn Edwards, Chief Executive Officer Daniel Elger, Director of Communications +44 (0) 7909 915068 Antisoma plc

Mark Court/Lisa Baderoon/Rebecca Sky
'"/>




Page: 1 2 3

Related medicine technology :

1. Data supporting three Antisoma programmes presented at AACR
2. Antisoma plc (UK) - Second lung cancer trial adds to positive data on AS1404
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that on December 24, ... offering. The Company raised approximately $2.3 ... intends to use the net proceeds from the ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... 23, 2011 Reportlinker.com announces that ... available in its catalogue: ... Analysis of Water and Wastewater Management ... http://www.reportlinker.com/p0506839/Global-Water-Market-Outlook-Strategic-Analysis-of-Water-and-Wastewater-Management-in-the-Pharmaceutical-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Water_dis ...
... PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Healthcare Conference in Palos Verdes, CA.  Josef von Rickenbach, Chairman ... PAREXEL at 4:00 p.m.  PT on Wednesday, June 8, 2011. ... available through the "Investors" section of PAREXEL,s website ...
Cached Medicine Technology:Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 2Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 3Reportlinker Adds Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry 4PAREXEL International to Present at Goldman Sachs Healthcare Conference and Jefferies Global Healthcare Conference 2
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas Sale, ... has chosen their best-selling lace wedding dresses, vintage bridesmaid ... season. , Now, BellasDress.com features popular women’s dresses, ... discount prices. The business hopes everyone can have a ... , “All our elegant products are made with exquisite ...
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... be closing in on a "fountain of youth" drug that ... of older adults, a new study suggests. Seniors received ... drug that targets a genetic signaling pathway linked to aging ... The experimental medication, a version of the ...
(Date:12/25/2014)... ” was featured on NewsWatch as part of its monthly ... the iOS, Android, and Windows markets. Andrew Tropeano, a mobile ... and shared with viewers how this is an application for ... “A picture says a thousand words.” It’s true. There are ... because each picture holds a unique and special meaning. Photos ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... March for Babies(R)WHITE PLAINS, N.Y., March 12 Liberty Tax Service ... the March of Dimes on March 27 will get their ... for Babies, the annual event from the March of Dimes ... For the second year, Liberty Tax Service is a ...
... obstructive pulmonary disease, research shows , , WEDNESDAY, March ... reason why one-quarter of smokers develop chronic obstructive ... with the serious breathing problem, U.S. researchers conclude. ... 880 long-term heavy smokers with and without COPD. ...
... Medical, Inc. (Nasdaq: SLTM ), a global leader ... Bank, a member company of SVB Financial Group (Nasdaq: ... million credit facility. "We are very pleased with this ... strategic initiatives in the aesthetic marketplace," said Stephen J. Fanning, ...
... The recent delivery of octuplets in Los Angeles was ... not obscure the risk of high-order multiple pregnancy. As ... outcome, with risk for mother and babies. With ... mostly preventable. Pacific Fertility Center has been taking steps to ...
... with one altruistic living donor, study explains, , , WEDNESDAY, ... young man stepped forward, willing to give one of ... 10 people had received new kidneys from that one ... the first nonsimultaneous, extended altruistic-donor (NEAD) chain. The woman ...
... in smog heightens lung, heart risks, report finds , , WEDNESDAY, ... each year from lung disease caused by atmospheric ozone, a ... living be in hot, dry cities such as Los Angeles, ... of Los Angeles may face a 25 percent to 30 ...
Cached Medicine News:Health News:Get Free Tax Preparation With Donation to Help Babies 2Health News:Solta Medical, Inc. Secures $9M Credit Facility from Silicon Valley Bank 2Health News:Octuplets Fiasco Could Have Been Prevented 2Health News:Octuplets Fiasco Could Have Been Prevented 3Health News:Living Kidney Donation Chains May Help More Get Transplants 2Health News:Living Kidney Donation Chains May Help More Get Transplants 3Health News:Ozone Pollution Taking Toll on American Lives 2Health News:Ozone Pollution Taking Toll on American Lives 3
... titanium alloy implants used for ... They are indicated where high ... SuperAnchor uses four Nitinol arcs ... small size. The unique design ...
... Super Revo Suture Anchor offers a simple ... mini-open rotator cuff repair. The cutting tip ... pre-threaded with two #2 strands of braided ... management are avoided with the Independent Suture ...
The Mini-Revo suture anchor is designed primarily for arthroscopic and open Bankart shoulder repair. Additional applications include other shoulder repair procedures, as well as use in small joints....
... Revo Suture Anchor offers a simple and ... rotator cuff repair. The cutting tip requires ... with two #2 strands of braided polyester ... are avoided with the Independent Suture Sliding ...
Medicine Products: